Physician profile
Krishna Ragothaman
NPI 1295738235
$2,870.26
in general payments reported to CMS, 2019-2025
25 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $495 · 2021: $304 · 2022: $389 · 2023: $284 · 2024: $523 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $992.00 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.45 | 2019-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $227.11 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $211.57 | 2019-2022 | |
| Lilly USA, LLC | $149.89 | 2019-2024 | Zepbound, Mounjaro |
| Pfizer INC. | $113.16 | 2021-2023 | |
| Abbvie INC. | $105.70 | 2022-2024 | |
| Glaxosmithkline, LLC. | $103.98 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $86.38 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $84.30 | 2019-2022 | |
| Mylan Specialty L.P. | $76.99 | 2021-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $74.42 | 2019-2023 | Eliquis |
| Exact Sciences Corporation | $66.31 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $61.36 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $44.18 | 2022-2025 | Evenity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $31.77 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.05 | 2019-2021 | |
| Corcept Therapeutics | $28.65 | 2023 | Korlym |
| Dexcom, INC. | $23.00 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $19.44 | 2022 | |
| Almatica Pharma LLC | $18.25 | 2022 | |
| Viatris Specialty LLC | $16.84 | 2025 | Yupelri |
| Biogen, INC. | $14.75 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.63 | 2019 | |
| Amarin Pharma, INC. | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Ragothaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.